Acute and chronic effects of oral enprostil, a synthetic dehydroprostaglandin E2, on uterine contractility.
In acute experiments eleven nonpregnant women received a single oral dose of enprostil (prostaglandin E2 analogue) 35-140 mcg. Uterine activity was measured by a microtransducer-tipped Millar catheter. A single, oral dose of enprostil caused a long-lasting contracture response of the uterus. 3 h after enprostil, uterine resting pressure (RP) was still high. In chronic experiments, eleven women with regular menstrual cycles received 35 mcg or 70 mcg BID enprostil and placebo in a crossover, double-blind fashion from cycle day 10 +/- 3 for four weeks, then had a washout period of four weeks followed by another four-week treatment period. An increase of uterine RP after enprostil was dose-dependent. After two weeks of twice-daily administration of enprostil, the baseline RP was lower than after placebo (p less than 0.01) and the increase in RP after the morning enprostil less than that seen on the first day. In eight patients studied, the mean values of plasma progesterone were normal, both during placebo--and enprostil--treated cycles.
Pulkkinen
M O
MO
Department of Obstetrics and Gynecology, University of Turku, Finland.
D000284:Administration, Oral; D002408:Catheters, Indwelling; D004305:Dose-Response Relationship, Drug; D004311:Double-Blind Method; D016620:Enprostil; D005260:Female; D006801:Humans; D008597:Menstrual Cycle; D011312:Pressure; D011459:Prostaglandins E, Synthetic / Q000008:administration & dosage / Q000494:pharmacology*; D013997:Time Factors; D014590:Uterine Contraction / Q000187:drug effects*
D011459:Prostaglandins E, Synthetic; D016620:Enprostil